MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a.

BACKGROUND & AIMS Hepatocellular carcinoma (HCC) is a heterogeneous tumor that develops via activation of multiple pathways and molecular alterations. It has been a challenge to identify molecular classes of HCC and design treatment strategies for each specific subtype. MicroRNAs (miRNAs) are involved in HCC pathogenesis, and their expression profiles have been used to classify cancers. We analyzed miRNA expression in human HCC samples to identify molecular subclasses and oncogenic miRNAs. METHODS We performed miRNA profiling of 89 HCC samples using a ligation-mediated amplification method. Subclasses were identified by unsupervised clustering analysis. We identified molecular features specific for each subclass using expression pattern (Affymetrix U133 2.0; Affymetrix, Santa Clara, CA), DNA change (Affymetrix STY Mapping Array), mutation (CTNNB1), and immunohistochemical (phosphor[p]-protein kinase B, p-insulin growth factor-IR, p-S6, p-epidermal growth factor receptor, β-catenin) analyses. The roles of selected miRNAs were investigated in cell lines and in an orthotopic model of HCC. RESULTS We identified 3 main clusters of HCCs: the wingless-type MMTV integration site (32 of 89; 36%), interferon-related (29 of 89; 33%), and proliferation (28 of 89; 31%) subclasses. A subset of patients with tumors in the proliferation subclass (8 of 89; 9%) overexpressed a family of poorly characterized miRNAs from chr19q13.42. Expression of miR-517a and miR-520c (from ch19q13.42) increased proliferation, migration, and invasion of HCC cells in vitro. MiR-517a promoted tumorigenesis and metastatic dissemination in vivo. CONCLUSIONS We propose miRNA-based classification of 3 subclasses of HCC. Among the proliferation class, miR-517a is an oncogenic miRNA that promotes tumor progression. There is rationale for developing therapies that target miR-517a for patients with HCC.

[1]  Derek Y. Chiang,et al.  IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. , 2010, Journal of hepatology.

[2]  Ming Yao,et al.  Gain of miR-151 on chromosome 8q24.3 facilitates tumour cell migration and spreading through downregulating RhoGDIA , 2010, Nature Cell Biology.

[3]  Jörn Bullerdiek,et al.  The Two Stem Cell MicroRNA Gene Clusters C19MC and miR-371-3 Are Activated by Specific Chromosomal Rearrangements in a Subgroup of Thyroid Adenomas , 2010, PloS one.

[4]  J. Llovet,et al.  miRNA delivery: emerging therapy for hepatocellular carcinoma. , 2010, Gastroenterology.

[5]  J. Llovet,et al.  Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. , 2010, Seminars in liver disease.

[6]  S. Lowe,et al.  miR-221 overexpression contributes to liver tumorigenesis , 2009, Proceedings of the National Academy of Sciences.

[7]  V. P. Collins,et al.  Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. , 2009, Cancer cell.

[8]  Thomas E. Royce,et al.  Whole-Genome Gene Expression Profiling of Formalin-Fixed, Paraffin-Embedded Tissue Samples , 2009, PloS one.

[9]  K. Tsai,et al.  Epigenetic control of the expression of a primate-specific microRNA cluster in human cancer cells , 2009, Epigenetics.

[10]  J. Yun,et al.  Effects of MicroRNA‐29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma , 2009, Hepatology.

[11]  Stephanie Roessler,et al.  MicroRNA expression, survival, and response to interferon in liver cancer. , 2009, The New England journal of medicine.

[12]  S. Thorgeirsson,et al.  Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic phenotype and gain of metastatic properties , 2009, Oncogene.

[13]  T. Takizawa,et al.  Human Villous Trophoblasts Express and Secrete Placenta-Specific MicroRNAs into Maternal Circulation via Exosomes1 , 2009, Biology of reproduction.

[14]  Derek Y. Chiang,et al.  Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. , 2009, Journal of hepatology.

[15]  Derek Y. Chiang,et al.  Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. , 2009, Cancer research.

[16]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[17]  Kathryn A. O’Donnell,et al.  Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model , 2009, Cell.

[18]  Ping Jin,et al.  MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells , 2009, Journal of Translational Medicine.

[19]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[20]  Derek Y. Chiang,et al.  Pivotal role of mTOR signaling in hepatocellular carcinoma. , 2008, Gastroenterology.

[21]  Kenji Ikeda,et al.  Gene expression in fixed tissues and outcome in hepatocellular carcinoma. , 2008, The New England journal of medicine.

[22]  W. L. Ruzzo,et al.  MicroRNA Discovery and Profiling in Human Embryonic Stem Cells by Deep Sequencing of Small RNA Libraries , 2008, Stem cells.

[23]  Derek Y. Chiang,et al.  Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. , 2008, Cancer research.

[24]  Ron Shamir,et al.  Comprehensive MicroRNA Profiling Reveals a Unique Human Embryonic Stem Cell Signature Dominated by a Single Seed Sequence , 2008, Stem cells.

[25]  Laura Pelletier,et al.  MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations , 2008, Hepatology.

[26]  Artemis G. Hatzigeorgiou,et al.  Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer , 2008, Proceedings of the National Academy of Sciences.

[27]  Sean McWilliam,et al.  Origin, evolution, and biological role of miRNA cluster in DLK-DIO3 genomic region in placental mammals. , 2008, Molecular biology and evolution.

[28]  R. Aharonov,et al.  MicroRNAs accurately identify cancer tissue origin , 2008, Nature Biotechnology.

[29]  Jin Woo Kim,et al.  EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. , 2008, Cancer research.

[30]  L. Lang FDA approves sorafenib for patients with inoperable liver cancer. , 2008, Gastroenterology.

[31]  Lin Zhang,et al.  The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis , 2008, Nature Cell Biology.

[32]  T. Golub,et al.  MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia , 2007, Proceedings of the National Academy of Sciences.

[33]  Jill P. Mesirov,et al.  Subclass Mapping: Identifying Common Subtypes in Independent Disease Data Sets , 2007, PloS one.

[34]  J. Zucman‐Rossi,et al.  Genetic diversity of hepatocellular carcinomas and its potential impact on targeted therapies. , 2007, Pharmacogenomics.

[35]  K. Ghoshal,et al.  MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. , 2007, Gastroenterology.

[36]  H. El‐Serag,et al.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.

[37]  Derek Y. Chiang,et al.  Genomics and signaling pathways in hepatocellular carcinoma. , 2007, Seminars in liver disease.

[38]  George P Cobb,et al.  microRNAs as oncogenes and tumor suppressors. , 2007, Developmental biology.

[39]  S. Boyault,et al.  Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets , 2007, Hepatology.

[40]  V. Mazzaferro,et al.  A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. , 2006, Gastroenterology.

[41]  S. Thorgeirsson,et al.  Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. , 2006, The Journal of clinical investigation.

[42]  J. Mesirov,et al.  GenePattern 2.0 , 2006, Nature Genetics.

[43]  T. Okanoue,et al.  Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues , 2006, Oncogene.

[44]  R. DePinho,et al.  Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[45]  Chang-Zheng Chen,et al.  MicroRNAs as oncogenes and tumor suppressors. , 2005, The New England journal of medicine.

[46]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[47]  H. Horvitz,et al.  MicroRNA expression profiles classify human cancers , 2005, Nature.

[48]  S. Thorgeirsson,et al.  Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling , 2004, Hepatology.

[49]  Jian-Bing Fan,et al.  A versatile assay for high-throughput gene expression profiling on universal array matrices. , 2004, Genome research.

[50]  C. Croce,et al.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[51]  D. Bartel MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[52]  C. Burge,et al.  Prediction of Mammalian MicroRNA Targets , 2003, Cell.

[53]  Pierre Baldi,et al.  A Bayesian framework for the analysis of microarray expression data: regularized t -test and statistical inferences of gene changes , 2001, Bioinform..

[54]  S. Schmid,et al.  Regulation of macropinocytosis by p21-activated kinase-1. , 2000, Molecular biology of the cell.

[55]  Kadhim,et al.  Inhibition of tumor growth with doxorubicin in a new orthotopically implanted human hepatocellular carcinoma model. , 2000, Hepatology research : the official journal of the Japan Society of Hepatology.

[56]  T. Yamane,et al.  Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. , 1982, Cancer research.

[57]  Wei Wu,et al.  MicroRNA-Based Therapeutics for Cancer , 2012, BioDrugs.

[58]  R. Weinberg,et al.  Tumour invasion and metastasis initiated by microRNA-10b in breast cancer , 2008, Nature.

[59]  R. Aharonov,et al.  Identification of hundreds of conserved and nonconserved human microRNAs , 2005, Nature Genetics.

[60]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[61]  D. Woodfield Hepatocellular carcinoma. , 1986, The New Zealand medical journal.